Patents by Inventor Samantha Grace Lyons KEYSER

Samantha Grace Lyons KEYSER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIPR-agonist compounds
    Patent number: 11897926
    Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: January 11, 2022
    Date of Patent: February 13, 2024
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
  • LONG ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20220288168
    Abstract: The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
    Type: Application
    Filed: March 2, 2022
    Publication date: September 15, 2022
    Inventors: Milata Mary ABRAHAM, Daniel Anthony BRIERE, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU
  • GIPR-AGONIST COMPOUNDS
    Publication number: 20220127315
    Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: January 11, 2022
    Publication date: April 28, 2022
    Inventors: Jorge ALSINA-FERNANDEZ, Andrea Renee GEISER, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU, William Christopher ROELL
  • GIPR-agonist compounds
    Patent number: 11254721
    Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
  • GIPR-AGONIST COMPOUNDS
    Publication number: 20210032299
    Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 29, 2020
    Publication date: February 4, 2021
    Inventors: Jorge ALSINA-FERNANDEZ, Andrea Renee GEISER, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU, William Christopher ROELL